ResearchMoz

Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

GBI Research
Published Date » 2012-12-14
No. Of Pages » 78
     
  Generic Growth Strategies Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs  
     
  Summary  
   
 GBI Research, the leading business intelligence provider, has released its latest research, Generic Growth Strategies Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs. The report provides a comprehensive overview of the generic drugs market in the US, the top five countries in the European Union (EU, covering the UK, France, Germany, Spain and Italy) and Japan. The report focuses on the detailed analysis of major strategies implemented by the top 10 generic companies in the generic drugs market along with company portfolios...
Table of Contents

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 10

2 Generic Growth Strategies - Introduction 11

3 Generic Growth Strategies - Market Overview 12
3.1 Overview of the Generics Market 12
3.1.1 Leading Generics Companies 12
3.1.2 Generics Market Share 14
3.2 Drivers and Restraints 15
3.2.1 Drivers 16
3.2.2 Restraints 21

4 Generic Growth Strategies - Regulatory Landscape 23
4.1 The US 23
4.1.1 Hatch-Waxman Act and ANDA 23
4.1.2 Shortening Market Exclusivity of Biopharmaceuticals and Impact on Generics 25
4.1.3 Pay-For-Delay Ban to be Detrimental to Innovators as Well as Generics 25
4.1.4 Cost-sharing of Generic Drugs 25
4.1.5 Impact of Supplemental Examination Provision of Patent Reform Act on Generics 26
4.1.6 Biologics Price Competition and Innovation Act Falls Short 26
4.2 Europe 28
4.2.1 Generic Penetration 28
4.2.2 Generic Substitution 29
4.2.3 Pricing and Reimbursement 29
4.2.4 Marketing Authorization for Generics 29
4.2.5 Generic Landscape in Leading European Markets 29
4.2.6 Common European Union Patent System 31
4.2.7 Tendering 32
4.2.8 Regulatory Landscape for Biosimilars 32
4.2.9 The Future of Biosimilars is Advancing Along a Path Smoothened by European Groundwork 32
4.3 Japan 33
4.3.1 Generics 33
4.3.2 Biosimilar 34

5 Generic Growth Strategies - Major Strategies 35
5.1 Authorized Generics 35
5.1.1 Case Study 37
5.2 Mergers and Acquisitions 37
5.2.1 Vertical Integration 39
5.2.2 Therapeutic Expansion - Biosimilars 39
5.3 Outsourcing 40
5.3.1 Outsourcing Opportunities in Biosimilars 40
5.3.2 Outsourcing is Also a Source of Income for Generics Companies 40
5.4 Marketing Partnership 41
5.4.1 Case Studies 41
5.5 Paragraph IV Certifications 42
5.5.1 Case Studies 42
5.5.2 Example of a Paragraph IV Challenge That Did Not Work Out for a Generic 42
5.6 R&D Strategies Employed by Key Players in the Generics Market 43
5.6.1 Super Generics 43
5.6.2 Biosimilars 44
5.7 Increasing Awareness and Acceptance 46

6 Generic Growth Strategies - Competitive Landscape 47
6.1 Teva Pharmaceutical Industries Limited 47
6.1.1 Overview 47
6.1.2 Revenue Analysis 47
6.1.3 Therapeutic Focus 48
6.1.4 Geographic Focus 48
6.1.5 Generic Growth Strategies 48
6.1.6 SWOT 51
6.2 Sandoz 52
6.2.1 Overview 52
6.2.2 Revenue Analysis 52
6.2.3 Therapeutic Focus 52
6.2.4 Geographic Focus 52
6.2.5 Generic Growth Strategies 53
6.2.6 SWOT 54
6.3 Mylan 55
6.3.1 Overview 55
6.3.2 Revenue Analysis 55
6.3.3 Therapeutic Focus 55
6.3.4 Geographic Focus 55
6.3.5 Generic Growth Strategies 57
6.3.6 SWOT 58
6.4 Watson 59
6.4.1 Overview 59
6.4.2 Revenue Analysis 59
6.4.3 Therapeutic Focus 59
6.4.4 Geographic Focus 59
6.4.5 Generic Growth Strategies 60
6.4.6 SWOT 61
6.5 Actavis 62
6.5.1 Overview 62
6.5.2 Revenue Analysis 62
6.5.3 Therapeutic Focus 62
6.5.4 Geographic Focus 62
6.5.5 Generic Growth Strategies 62
6.5.6 SWOT 63
6.6 Hospira 64
6.6.1 Overview 64
6.6.2 Revenue Analysis 64
6.6.3 Therapeutic Focus 64
6.6.4 Geographic Focus 64
6.6.5 Generic Growth Strategies 65
6.6.6 SWOT 66
6.7 Sanofi 67
6.7.1 Overview 67
6.7.2 Revenue Analysis 67
6.7.3 Geographic Focus 67
6.7.4 Generic Growth Strategies 67
6.7.5 SWOT 68
6.8 Daiichi Sankyo 68
6.8.1 Overview 68
6.8.2 Revenue Analysis 68
6.8.3 Geographic Focus 68
6.8.4 Generic Growth Strategies 68
6.8.5 SWOT 69
6.9 Aspen 69
6.9.1 Overview 69
6.9.2 Revenue Analysis 69
6.9.3 Geographic Focus 69
6.9.4 Generic Growth Strategies 70
6.9.5 SWOT 70
6.10 STADA 71
6.10.1 Overview 71
6.10.2 Revenue Analysis 71
6.10.3 Therapeutic Focus 71
6.10.4 Geographic Focus 71
6.10.5 Generic Growth Strategies 72
6.10.6 SWOT 72

7 Generic Growth Strategies - Conclusion 73

8 Generic Growth Strategies - Appendix 74
8.1 Market Definitions 74
8.2 Abbreviations 74
8.3 Bibliography 75
8.4 Research Methodology 77
8.4.1 Coverage 77
8.4.2 Secondary Research 77
8.4.3 Primary Research 78
8.4.4 Expert Panel Validation 78
8.5 Contact Us 78
8.6 Disclaimer 78

List of Tables


Table 1: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010-2011 13
Table 2: Generic Growth Strategies, Global, Revenues of Major Drugs Due for Patent Expiry ($m), 2013-2020 17
Table 3: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006-2011 18
Table 4: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011-2012 19
Table 5: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007-2012 20
Table 6: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006-2012 22
Table 7: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011-2020 26
Table 8: Generic Growth Strategies, Notable Authorized Generics Entry, The US, 2010-2012 35
Table 9: Generic Growth Strategies, Generic Products Launched, Teva, The US, 2011 49
Table 10: Generic Growth Strategies, Top Five Generic Active Ingredients, STADA Group, Revenue ($m), 2011 71

List of Figures


Figure 1: Generic Growth Strategies, Global, Revenues of Leading Generic Companies ($bn), 2010-2011 13
Figure 2: Generic Growth Strategies, Generic Market Share in Selected Countries, 2010 14
Figure 3: Generic Growth Strategies, Drivers and Restraints, 2012 15
Figure 4: Generic Growth Strategies, Global, Revenues of Top 10 Drugs Due for Patent Expiry ($m), 2013-2020 16
Figure 5: Generic Growth Strategies, Number of Generic ANDA Filed and Approvals, 2006-2011 18
Figure 6: Generic Growth Strategies, ANDA Approvals by Month, The US, 2011-2012 19
Figure 7: Generic Growth Strategies, Number of EMA Authorized Generics, Europe, 2007-2012 20
Figure 8: Generic Growth Strategies, Number of Biosimilars Authorized by the EMA, Europe, 2006-2012 22
Figure 9: Generic Growth Strategies, The US, Generic Drug Cost-Sharing (%), 2011-2020 25
Figure 10: Generic Growth Strategies, SWOT Analysis, Teva, 2012 51
Figure 11: Generic Growth Strategies, SWOT Analysis, Sandoz, 2012 54
Figure 12: Generic Growth Strategies, SWOT Analysis, Mylan, 2012 58
Figure 13: Generic Growth Strategies, SWOT Analysis, Watson, 2012 61
Figure 14: Generic Growth Strategies, SWOT Analysis, Actavis, 2012 63
Figure 15: Generic Growth Strategies, SWOT Analysis, Hospira, 2012 66
Figure 16: Generic Growth Strategies, SWOT Analysis, Sanofi, 2012 68
Figure 17: Generic Growth Strategies, SWOT Analysis, Daiichi Sankyo, 2012 69
Figure 18: Generic Growth Strategies, SWOT Analysis, Aspen, 2012 70
Figure 19: Generic Growth Strategies, SWOT Analysis, STADA Arzneimittel AG, 2012 72

Upcoming Reports:

Testosterone Replacement Therapy (TRT) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The testosterone replacement therapy is a process of giving testosterone when testes do not produce sufficient amount of testosterone because of injury, damage or absence. The testosterone replacement therapy has gained the momentum in last decade with high penetration in surgery market. The testosterone replacement therapy market could be segmented into 3 categories based on the type of product, into the following sub segments: gel, patches and other. Increasing awareness of testosterone treatment and hypogonadism and increasing surging aging populace with high disposable will...
Heart Blocks Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Heart block is a disease of electrical system of the heart that controls the rate and rhythm of the heart. A heart block occurs if there is slowed and disturbed electrical signals while travelling to heart. People have inherited congenital heart blocks as well as acquired heart blocks that develop after birth. Based on the working of electric signal, heart block is of two type’s namely partial heart block and complete heart block. In partial heart block, the electrical signals are blocked partially i.e., their arrival to the heart is delayed. In complete heart block, signals...
Rheumatoid Arthritis Pharmacotherapeutics Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Treatment options for rheumatoid arthritis (RA) are expanding as a result of increasing research activities and more explicit understanding of the pathophysiology of diseases. For the treatment of RA, novel selective inhibitors such as cyclooxygenase-2 (COX-2) are used along with the non-steroidal anti-inflammatory drugs. Although COX-2 is used in treatment of RA, it has several side effects associated with the upper gastrointestinal region.  Currently, use of disease modifying antirheumatic drugs is recommended by most professionals in the early stages of disease. ...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

British Stocks Fell Flat after Decline in Retail Sales
Apr 23, 2015  
The shares of the top British companies were left mostly unchanged on Thursday, April 23, 2015, after an unforeseen fall in the national retail sales for this month making up for an increase in the utilities shares just 2 weeks before the general election. Whereas the expectation for a single party to win an outright majority on May 7, 2015 is very low, and the experts forecasting a...
Retail Clinics Touched 10 Million Annual Visits
Apr 23, 2015  
The proliferation of retail health means Americans are visiting retail clinics more than 10 million times a year at 1,800-plus locations, yet this convenient and low cost care model accounts for just a fraction of primary care in the U.S. Manatt Health, a health care consulting firm, said retail clinics represent about 2% of “all primary care encounters” in the U.S. even with the...
China Imposes a Fine on Mercedes of US$57 million
Apr 23, 2015  
A Chinese regulator said Thursday it has fined Mercedes Benz US$57 million on price-fixing charges in a wide-ranging probe of the auto industry that has prompted complaints foreign automakers are being treated unfairly. The unit of Germany's Daimler AG was fined for violating anti-monopoly law by enforcing minimum prices dealers were required to charge for vehicles and replacement parts,...
Zinc to Surpass Gold for Personal Portfolios
Apr 23, 2015  
The precious metals such as gold are in low gear, although miners are trying to have a better look. A lot of the Oxford Club Members are trying to give a fill to their metal portfolios.  There is speculation about zinc to outperform this year. Since mid March, the metal is up by 12.9% already. The numbers are much better than gold and market estimates are it is going to go even...
Copper Traders in the World Bracing for Inventory
Apr 23, 2015  
The copper traders in the world are in a dreaded state. China which is large consumer of copper has withdrawn demand due to slowdown of building boom, and market data for the week elucidates higher volumes consumed for intermediate copper concentrates rather than the finished material which has been the mainstay of global trade. It is sign of further tough times for copper traders, as...